South Plains Financial Inc. acquired a new stake in shares of Stryker Co. (NYSE:SYK - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,995 shares of the medical technology company's stock, valued at approximately $718,000.
Several other hedge funds have also recently modified their holdings of SYK. Kohmann Bosshard Financial Services LLC bought a new position in shares of Stryker during the 4th quarter valued at about $25,000. Rakuten Securities Inc. grew its holdings in Stryker by 618.2% during the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after buying an additional 68 shares in the last quarter. Centricity Wealth Management LLC purchased a new position in Stryker during the 4th quarter valued at approximately $30,000. BankPlus Trust Department purchased a new stake in shares of Stryker during the 4th quarter worth approximately $33,000. Finally, VSM Wealth Advisory LLC bought a new position in shares of Stryker during the 4th quarter valued at approximately $36,000. Hedge funds and other institutional investors own 77.09% of the company's stock.
Insider Buying and Selling at Stryker
In related news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company's stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 5.90% of the company's stock.
Stryker Stock Up 1.2 %
Shares of SYK stock traded up $4.61 on Friday, hitting $378.60. The stock had a trading volume of 3,709,100 shares, compared to its average volume of 1,355,896. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The business has a 50 day moving average price of $366.38 and a 200 day moving average price of $373.82. The company has a market cap of $144.51 billion, a PE ratio of 48.79, a P/E/G ratio of 2.93 and a beta of 0.93. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.
Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.73 by $0.11. The business had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.68 billion. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The company's quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.50 EPS. Research analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current fiscal year.
Stryker Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were issued a $0.84 dividend. The ex-dividend date of this dividend was Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.89%. Stryker's dividend payout ratio is presently 45.41%.
Wall Street Analyst Weigh In
Several equities analysts have commented on the stock. Needham & Company LLC reiterated a "buy" rating and set a $442.00 price objective on shares of Stryker in a research report on Friday, March 21st. Canaccord Genuity Group boosted their price objective on Stryker from $420.00 to $435.00 and gave the stock a "buy" rating in a research note on Wednesday, January 29th. Stifel Nicolaus boosted their price objective on Stryker from $400.00 to $440.00 and gave the stock a "buy" rating in a research note on Wednesday, January 29th. Royal Bank of Canada boosted their target price on Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a research report on Wednesday, January 29th. Finally, JPMorgan Chase & Co. raised their price target on Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $426.53.
Check Out Our Latest Stock Report on SYK
About Stryker
(
Free Report)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
See Also
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
